|Bid||0.0000 x 1800|
|Ask||0.0000 x 3000|
|Day's Range||1.8200 - 2.1000|
|52 Week Range||0.6000 - 3.2500|
|Beta (3Y Monthly)||3.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.
Shares of Daré Bioscience Inc. rocketed 129% on very heavy volume toward a 13-month high in afternoon trade Monday, after the biopharmaceutical company announced positive findings for the use of its DARE-VVA1 product candidate in treating vulvar and vaginal atrophy (VVA). The stock was the biggest percentage gainer listed on major U.S. exchanges, even though it pared earlier gains of as much as 253%. Volume swelled to 37.8 million shares, compared with the full-day average of about 82,500 shares and enough to make the stock the most active on the Nasdaq exchange. The company said a self-administered vaginal suppository containing tamoxifen administered to four healthy postmenopausal women with VVA showed "significant improvements" in reducing vaginal pH and vaginal dryness, without significant absorption of tamoxifen. "If successful, DARE-VVA1 could be the first and only vaginally administered tamoxifen product approved by the FDA for the treatment of VVA in hormone-receptor positive breast cancer patients," the company said in a statement. The stock has now more than tripled year to date (up 218%), while the iShares Nasdaq Biotechnology ETF has climbed 18% and the S&P 500 has gained 13%.
SAN DIEGO, March 18, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the publication of clinical findings for vaginally-administered tamoxifen in Clinical and Experimental Obstetrics and Gynecology, a leading international journal for publication of research focused on the development of new therapeutic interventions for obstetrics and gynecology. Daré’s product candidate, DARE-VVA1, incorporates tamoxifen in a proprietary formulation designed for vaginal delivery. Daré holds the exclusive worldwide rights to patents issued in the U.S. and Japan covering the use and delivery of DARE-VVA1 for vulvar and vaginal atrophy (VVA) and a U.S. patent covering composition, use and delivery of DARE-VVA1 for VVA.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it received a second Notice of Award of $982,851, part of a grant providing up to $1.9 million in the aggregate for Ovaprene® research from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). This second award, an additional $982,851, followed the NIH’s review of an interim data analysis and other results of the first phase of work. The award will be applied to important clinical development efforts supporting Ovaprene, a potential first-in-class hormone-free contraceptive solution.
SAN DIEGO, March 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 16th Annual BIO Asia International Conference on Tuesday, March 5, 2019 at 4:15 p.m. Japanese Standard Time in Tokyo, Japan. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments. “Given our focus on identifying development and global commercialization partners for our portfolio of women’s health product candidates, we are pleased to have the opportunity to present and participate in the partnering meetings organized by the conference,” said Sabrina Johnson.
SAN DIEGO, Feb. 05, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive.
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré.
The big shareholder groups in Daré Bioscience, Inc. (NASDAQ:DARE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
Dare Bioscience (DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline and their potential eventual related commercialization opportunities. Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC. DARE is also required to pay potential future milestones based on “clinical, regulatory, commercial launch and sales events”, and is also subject to paying royalties on any eventual sales. Bacterial Vaginosis, What It Is, How Prevalent and How Is it Treated?
CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling patients in an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% in normal healthy women. Sildenafil, the active ingredient in Sildenafil Cream, 3.6%, is marketed in an oral dosage form under the brand name Viagra® for the treatment of erectile dysfunction in men.
SAN DIEGO, Nov. 13, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018, to provide a corporate update and to discuss the Company's financial results for the quarter ended September 30, 2018. To access the conference call via phone, dial (844) 831-3031 (domestic) or (443) 637-1284 (International). The conference ID number for the call is 5463588.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place November 4-7, 2018 in Washington D.C. The presentations will focus on recently completed studies demonstrating pharmacokinetics and tolerability of DARE-HRT1, a novel 17β- estradiol and progesterone intravaginal ring being developed for the treatment of vasomotor symptoms (VMS) commonly associated with the onset of menopause, and DARE-FRT1, a novel progesterone intravaginal ring (IVR) being developed for potential utilization in both in-vitro fertilization (IVF) and pre-term birth. “The compelling preclinical results demonstrate the ability to achieve target pharmacokinetic and tolerability objectives for both a single active IVR (DARE-FRT1) and dual active IVR (DARE-HRT1),” said Dr. David Friend, Daré’s Chief Scientific Officer.
Daré (DARE) continues to not only move their various development programs forward, but also continues to add promising candidates to their high-potential women’s health-focused pipeline. Relative to the latter, DARE’s most recent pipeline addition, CatSper, a potential first-in-kind contraceptive for both men and women, was announced in mid-July.